Alunbrig (brigatinib) is a small molecule pharmaceutical. Brigatinib was first approved as Alunbrig on 2017-04-28. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. It is known to target epidermal growth factor receptor, insulin receptor, ALK tyrosine kinase receptor, and insulin-like growth factor 1 receptor. Alunbrig's patents are valid until 2035-11-10 (FDA).
|Indication||non-small-cell lung carcinoma|
|Drug Class||Tyrosine kinase inhibitors|